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Background
Atrial fibrillation (AF) is the most com-
mon sustained cardiac arrhythmia occur-
ring in about 1 % of the general popula-
tion (10 % of all people aged > 80 years are 
suffering from AF) [1]. Over 6 million Eu-
ropeans suffer from this arrhythmia and 
its prevalence is estimated to increase sig-
nificantly within the next decades as the 
population ages and manifests more co-
morbidities [2, 3].
AF is associated with a doubling of 
overall mortality and a fivefold increased 
risk of stroke [4, 5]. Clinical symptoms 
may include palpitations, dyspnoea or 
syncopes with significant impairment of 
quality of life (QoL). On the other hand 
AF can also occur unnoticed unless inci-
dentally found or until complications oc-
cur [2, 6]. A number of newer investiga-
tions, which used a non-interventional 
design similar to ours, showed substan-
tially compromised QoL in AF patients 
[7−12].
Dronedarone is an antiarrhythmic 
drug which has a benzofuran moiety as 
amiodarone but does not possess the io-
dine part affecting thyroid function [13]. 
Due to differences such as a methyl sul-
phonyl group the lipophilicity of the new 
agent compared with amiodarone was re-
duced and its plasma half-life substantial-
ly shortened thought to reduce organ tox-
icity due to cumulative effects.
The drug has been launched in 2010 
in Germany under the brand name Mul-
taq®. Based on the results of new trials 
and pharmacovigilance reports its label-
ling has been amended several times. Ac-
cording to the current summary of prod-
uct characteristics, Multaq® is indicated 
for the maintenance of sinus rhythm af-
ter successful cardioversion in adult clin-
ically stable patients with paroxysmal or 
persistent AF [14]. Due to its safety pro-
file, the agent should only be prescribed 
after alternative treatment options have 
been considered. Multaq® should not be 
given to patients with left ventricular sys-
tolic dysfunction or to patients with cur-
rent or previous episodes of heart failure 
[14]. Careful monitoring during drone-
darone administration is recommended 
with regular assessment of cardiac, he-
patic and pulmonary function.
While dronedarone has been exten-
sively documented in the context of clin-
ical studies [15], there is a paucity of da-
ta on the use under real life conditions, 
with the exception of a retrospective da-
tabase analysis of all patients treated with 
the drug between 2010 and 2012 in Swe-
den [16]. The real life patient population 
often differs from patient cohorts in con-
trolled clinical studies with regards to de-
mographic characteristics, comorbidi-
ties and concomitant diseases. Data col-
lected in non-interventional studies like 
IMPULS can complement the findings of 
pivotal studies. We aimed to collect such 
data, with particular focus on QoL.
Methods
Study design and timelines. IMPULS 
was a prospective multicentre non-inter-
ventional study (NIS) according to § 67 
(6) German Drug Law (AMG) to docu-
ment the management/treatment of con-
secutive patients treated with Multaq® 
over a period of 12 months. All proce-
dures followed were in accordance with 
the ethical standards with the Helsinki 
Declaration of 1975 (in its most recent-
ly amended version). The study materi-
als were reviewed and approved by the 
ethics committees of the Ärztekammer 
Westfalen-Lippe and of the Medical Fac-
ulty of Wilhelms University of Münster. 
Informed consent was obtained from all 
patients included in the study. The study 
was performed between January 2012 
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(first patient in) and December 2013 (last 
patient out).
Centres. Office-based cardiologists, gen-
eral practitioners and internists were eli-
gible for participation. Selection of centres 
aimed to obtain a representative distribu-
tion with respect to geography and physi-
cian specialisation, respectively.
Patients. Patients were eligible for doc-
umentation, if they (1) were newly treat-
ed with dronedarone or were on main-
tenance treatment with dronedarone no 
longer than 3 months; (2) had paroxys-
mal or persistent AF and at least one car-
diovascular risk factor (arterial hyperten-
sion, diabetes mellitus, previous stroke, 
transient ischaemic attack, arterial em-
bolism, left atrial diameter ≥ 50 mm); (3) 
had provided written informed consent to 
participate in the study. No explicit exclu-
sion criteria were applied to avoid selec-
tion bias. All diagnoses were provided by 
the treating physician and were not adju-
dicated by third parties.
No diagnostic measures or treatment 
methods were stipulated, but remained in 
the sole responsibility of the participating 
physicians. At baseline and after approxi-
mately 6 and 12 months, respectively, the 
physicians documented diagnostic and 
therapeutic parameters as assessed under 
routine treatment or as available from ad-
ditional sources such as, e.g., hospital re-
ports or patient charts.
In addition, patients were asked to 
complete QoL questionnaires at base-
line and at their 6-month (FU1) and 
12-month follow-up (FU2) visits at the 
physician’s office. As generic instru-
ments, the 100-point EQ-5D visual ana-
logue scale (VAS) [17] and the short form 
12 (SF-12) [18] were applied. Further, the 
AF-QoL questionnaire as disease-specific 
questionnaire was administered [19, 20].
Parameters. At baseline, characteris-
tics on demographics (gender, age and 
employment status), basic data and vital 
signs, cardiac risk factors, cardiac histo-
ry and concomitant diseases were noted. 
Particular focus was on hepatic function 
(recording of last alanine aminotransfer-
ase (ALT) values, renal function (creati-
nine value)), and in the case of vitamin K 
treatment, the international normalised 
ratio.
With regards to AF, the following in-
formation was documented: month of 
first diagnosis, type, current rhythm ac-
cording to last ECG and symptoms. Fur-
ther, therapy within the last 12 months, 
hospitalisations due to AF or other rea-
sons, current therapy for the prevention 
of thromboembolic complications, man-
agement of AF in the last 12 months were 
documented. At 3 months, ALT and cre-
atinine values between the initiation of 
dronedarone therapy and the visit were 
noted.
At the two FU visits at 6 months and 
12 months, physicians predominantly 
documented current symptoms, therapy 
for AF and anticoagulation, newly occur-
ring vascular events (transient ischaemic 
attacks, stroke, myocardial infarction, 
heart failure or other cardiac events) and 
detailed information on cardioversion 
or other therapy. Medication for rhythm 
control of AF was recorded by Vaughan-
Williams classification.
Data entry and analysis. Data were col-
lected using paper–pencil case record 
forms. Duplicate data entry was per-
formed by the contract research organ-
isation, and plausibility checks were exe-
cuted using a validation plan.
The safety set consisted of 549 pa-
tients, the enrolled set of 534 patients and 
the full analysis set of all patients treated at 
least once with dronedarone and FU data 
available for 342 patients (. Fig. 1).
Statistical analysis
Continuous variables are reported as 
mean with standard deviation, categori-
cal variables as percentage of patient pop-
ulation. Due to incomplete answers and 
multiple answering options, observed 
numbers and percentages do not always 
add up to exactly 100 %. Comparisons 
between baseline and FU were performed 
with the two-tailed Student’s paired sam-
ple t-test. Data were analysed using the 
SAS statistical package Version 9.2.
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Enrolled set for efficacy analysis
n = 534
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A total of 161 office-based cardiolo-
gists, general practitioners and internists 
throughout Germany took part in this 
study.
Patient characteristics. Characteristics 
of patients are displayed in . Table 1. 
Mean age of patients was 66.3 years, 
57.3 % were men. Patients had paroxys-
mal AF in 71.4 % and persistent AF in 
26.6 % (missing 2.1 %). Comorbidities 
were frequent, in particular arterial hy-




AF-QoL. The AF-QoL psychological do-
main improved from 44.6 ± 22.6 at base-
line to 56.7 ± 21.7 at FU1 (i.e. + 12.1 ± 20.8 
points, p<0.0001), and to 60.6 ± 22.6 at 
FU2 (+ 16.0 ± 23.5 points, p<0.0001). Fur-
ther, the AF-QoL physical domain im-
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Abstract
Background and aims. The multichan-
nel blocker dronedarone is currently indicat-
ed for the maintenance of sinus rhythm af-
ter successful cardioversion in adult clinical-
ly stable patients with paroxysmal or persis-
tent atrial fibrillation (AF), with careful moni-
toring of cardiac, hepatic and renal function. 
We aimed to investigate patients’ quality of 
life (QoL) and tolerability and effectiveness of 
dronedarone under real life conditions.
Methods. In the 1-year prospective, non-in-
terventional IMPULS study, 161 office-based 
cardiologists, general practitioners and inter-
nists throughout Germany documented 549 
patients with AF who were currently or new-
ly prescribed dronedarone (safety set, SS). Of 
those, 342 patients (full analysis set, FAS) pro-
vided data on QoL at baseline, 6 months and 
12 months).
Results. Mean age of patients was 67.6/66.3 
years; 53.0 %/57.3 % were men (SS/FAS). 
AF type at inclusion in the SS/FAS was par-
oxysmal in 71.9 %/71.3 % and persistent in 
26.0 %/26.6 % (missing in 2.0 %/2.0 %). The 
proportion of patients in sinus rhythm in-
creased from 44.6 % at baseline to 70.2 % 
(SS). The mean value on the 100-point visu-
al analogue scale (EuroQol EQ-5D) increased 
from 62.3 ± 17.1 at baseline by 11.4 ± 18.7 
points (FAS, p<0.0001). The AF-QoL Psycho-
logical Domain improved from 44.6 ± 22.6 
at baseline by 16.0 ± 23.5 points at 1 year 
(p<0.0001), the AF-QoL physical domain from 
49.5 ± 22.1 by 10.9 ± 22.5 points (p<0.0001), 
and the AF-QoL sexual domain from 
61.8 ± 27.1 by 6.6 ± 28.2 points (p<0.0001). In 
all, 136 patients (24.8 % of all patients in the 
safety set) had at least one adverse drug reac-
tion (ADR) causally related to dronedarone.
Conclusions. Various dimensions of quali-
ty of life of patients with AF were improved 
on dronedarone under clinical practice con-
ditions. No previously unknown safety issues 
were noted.
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Sicherheit und Lebensqualität bei Patienten mit Vorhofflimmern unter Therapie mit Dronedaron: 
prospektive, nicht-interventionelle Studie über 1 Jahr in der ambulanten Versorgung in Deutschland
Zusammenfassung
Hintergrund und Ziele. Der Mehrkanal- 
blocker Dronedaron ist – nachdem alternative 
Behandlungsoptionen in Erwägung gezo-
gen wurden – angezeigt zum Erhalt des Si-
nusrhythmus nach einer erfolgreichen Kardio-
version bei erwachsenen, klinisch stabilen Pa-
tienten mit paroxysmalem oder persistieren-
dem Vorhofflimmern (VHF). Die kardiale, he-
patische und renale Funktion sind zu kont-
rollieren. Wir untersuchten die Lebensquali-
tät der Patienten unter Dronedaron sowie die 
Verträglichkeit und Wirksamkeit der des Anti-
arrhythmikums unter Praxisbedingungen.
Methoden. In der prospektiven, nicht-inter-
ventionellen IMPULS-Studie dokumentier-
ten 161 niedergelassene Kardiologen, haus-
ärztlich tätige Internisten und Allgemeinärz-
te in Deutschland 549 Patienten mit VHF (Sa-
fety Set (SS)), die bereits Dronedaron erhiel-
ten oder denen die Substanz erstmalig ver-
schrieben wurde. Davon hatten 342 Patien-
ten (Full-Analysis Set, FAS) Daten zur Lebens-
qualität zu Beginn der Studie sowie nach 6 
und 12 Monaten.
Das mittlere Alter der Patienten lag bei 
67,6/66,3 Jahren und 53,0 %/57,3 % waren 
Männer (SS/FAS). Hinsichtlich des VHF-Typs 
wurde die paroxysmale Manifestation bei 
71,9 %/71,3 % und die persistierende bei 
26,0 %/26,6 % angegeben (fehlende Angabe 
bei 2,0 %/2,0 %;) (SS/FAS). Der Anteil der Pa-
tienten im Sinusrhythmus nahm von 44,6 % 
bei Dokumentationsbeginn auf 70,2 % nach 
1 Jahr zu (SS). Die Lebensqualität verbesser-
te sich auf der 100-stufigen visuellen Analog-
skala (EuroQol EQ-5D) von 62,3 ± 17,1 Punk-
ten um 11,4 ± 18,7 Punkte (FAS; p<0,0001). 
Hinsichtlich der Dimension „psychische Be-
einträchtigung“ im AF-QoL (Ausgangsmit-
telwert ± SD 44,6 ± 22,6) wurde eine Verbes-
serung von 16,0 ± 23,5 Punkten nach 1 Jahr 
dokumentiert. Bei „körperliche Beeinträch-
tigung“ (von 49,5 ± 22,2) betrug die Verbes-
serung 10,9 ± 22,5 Punkte (p<0.0001), und 
bei „Sexualität“ (von 61,8 ± 27,1 Punkten) 
6,6 ± 28,2 Punkte (p<0.0001). Nebenwirkun-
gen, die vom dokumentierenden Arzt als 
möglicherweise oder sicher in Beziehung zu 
Dronedaron stehend eingestuft wurden (un-
erwünschte Arzneimittelwirkungen, UAW), 
traten bei 136 Patienten auf (24,8 % des SS).
Schlussfolgerung. Unter Alltagsbedingun-
gen verbesserten sich verschiedene Dimen-
sionen der Lebensqualität während der The-
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proved from 49.5 ± 22.2 at baseline to 
59.8 ± 20.5 at FU1 (i.e. + 10.3 ± 19.5 points, 
p<0.0001), and to 60.3 ± 24.0 at FU2 
(+ 10.9 ± 22.5 points, p<0.0001). Final-
ly, the AF-QoL sexual domain improved 
from 61.8 ± 27.1 at baseline to 68.3 ± 24.8 
at FU1 (i.e. + 6.5 ± 24.2, p<0.0001), and 
to 68.4 ± 26.7 at FU2 (+ 6.6 ± 28.2 points, 
p<0.0001).
EQ-5D. The mean value on the 100-point 
VAS increased from 62.3 ± 17.1 at base-
line to 73.1 ± 17.0 at FU1 (+ 10.8 ± 17.9 
points, p<0.0001) and to 73.9 ± 17.3 at 
FU2 (+ 11.4 ± 18.7 points, p<0.0001).
For both the AF-QoL and the EQ-5D, 
there were no important differences be-
tween men and women or in patients with 
paroxysmal versus persistent AF.
Secondary effectiveness variables
SF-12. The mean SF-12 physical summa-
ry scale increased from 42.3 ± 8.6 points 
at baseline to 46.2 ± 7.9 at FU1 (+ 4.0 ± 8.6 
points, p<0.0001) and to 46.5 ± 9.0 
(+ 4.3 ± 9.3 points, p<0.0001) at FU2. The 
mental summary scale increased from 
43.4 ± 11.9 points at baseline to 47.9 ± 10.0 
at FU1 (+ 4.4 ± 10.3 points, p<0.0001) and 
to 48.1 ± 9.8 (+ 4.8 ± 11.3 points, p<0.0001) 
at FU2.
Rhythm control rates. The proportion of 
patients in sinus rhythm increased from 
44.6 % at baseline to 70.2 % at FU1 and 
70.9 % at FU2.
General health evaluation. While at 
baseline, the great majority of patients re-
ported at least slight or moderate impair-
ment of their general health, at FU their 
self-reported state had considerably im-
proved (. Fig. 2).
Safety and tolerability (safety set)
Overall assessment. A total of 281 indi-
vidual adverse drug reactions causally re-
lated to Multaq®, of which 165 were rat-
ed as serious and 116 as non-serious, were 
reported in 136 patients (24.6% of all pa-
tients in the safety set, . Table 2). Most 
serious ADRs (SADR) occurred in the 
category ‘cardiac disorders’ (94 SADRs), 
followed by ‘general disorders and admin-
istration site conditions’ (23 SADRs), ‘in-
vestigations’ (18 SADRs) and ‘respirato-
ry, thoracic and mediastinal disorders’ (11 
SADRs).
AF was the most frequently noted SADR 
(in 13.8 % of patients). All other events oc-
curred in less than 2 % (e.g. drug ineffec-
tiveness in 1.5 %, heart failure in 1.3 % and 
dyspnoea in 1.3 %). The most frequent 
non-serious ADRs were increased ALT 
(2.0 % of patients), nausea (1.3 %) and di-
arrhoea (1.3 %); all other events were not-
ed less than 1 %.
Out of the 136 patients with SADR or 
ADR, a total of 110 discontinued Mul-
taq® therapy. The most frequently noted 
underlying conditions (. Table 3) were 
AF (10.4 % of patients), increased ALT 
(2.2 % of patients), dyspnoea (2.2 % of pa-
tients) and drug ineffectiveness (1.6 % of 
patients).
Laboratory values. ALT values were in-
creased at least 3 times above the upper 
reference limit in 60 patients (10.9 %). 
There was no specific time pattern in the 
occurrence of the elevations.
Elevations of creatinine at least 2 times 
above the upper reference limit were not 
documented in this study.
Discussion
To the best of our knowledge, the IM-
PULS study is the only prospective obser-
vational study that specifically documents 
the use of dronedarone under clinical 
practice conditions. Previous similar AF 
studies in Germany such as MOVE [21] 
or ATRIUM [22] were performed too ear-
ly to accrue significant patient numbers.
IMPULS used similar inclusion crite-
ria as the ATHENA study and focused on 
patients with AF who had additional risk 
factors for death [23]. In that study, pa-
tients in the dronedarone group had high-
er rates of bradycardia, QT-interval pro-
longation, nausea, diarrhoea, rash and an 
increased serum creatinine level than the 
placebo group, whereas rates of thyroid- 
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Table 1 Demographic variables AF type and comorbidies inclusion (FAS, n = 342)
Variable n Value
Age, years (mean) 342 66.3 ± 9.7
< 65 years (%) 134 39.2
 ≥ 65 years (%) 208 60.8
Gender, male (%) 196 57.3
 Female (%) 146 42.7





AF duration, days (median) 334 396
Comorbidities (%)
Arterial hypertension 321 93.9
Diabetes mellitus 80 23.4
Hyperthyreosis 13 3.8
Pathological alcohol consumption 4 1.2
Stroke/TIA 24 7.0
Left atrial diameter ≥ 50 mm 47 13.7
Valvular defect 60 17.5
Coronary artery disease 74 21.6
Table 2 Overview on adverse drug reactions (ADR)
Category Events (n) Patients (n) % of patients at risk
Any ADR related 281 136 24.8
Non-serious ADR 116 57 10.4
Serious ADR 165 92 16.8
and pulmonary-related adverse events 
were not significantly different between 
the two groups. Dronedarone reduced the 
incidence of hospitalisation due to cardio-
vascular events or death [23].
In our study, dronedarone was well-
tolerated, and the reported adverse drug 
reactions were in line with current knowl-
edge. The most frequently reported rea-
son for drug withdrawal was recurrence 
of AF and therefore not related to safe-
ty per se. With respect to laboratory val-
ues, the rate of abnormal liver function 
tests was substantially higher in IMPULS 
(10.9 %) compared with ATHENA (0.5 %) 
which might be due to the fact that in the 
latter trial there were no scheduled hepat-
ic tests. Conversely, in ATHENA an in-
crease in serum creatinine was noted in 
4.7 %, compared with 0 % in our study. 
A recent retrospective database analysis 
on all 4856 patients treated with drone-
darone in Sweden during 2010–2012, i.e., 
before the implementation of restrictions 
in the labelling of the drug, showed that 
patients selected for treatment were low-
risk and had lower mortality than expect-
ed from the general population, or than 
AF patients on other antiarrhythmic 
medication [16]. Further, the risk of inci-
dent liver disease was significantly lower 
among dronedarone patients than among 
other AF patients (HR 0.57; 95 % CI 0.34–
0.92) [16].
It is important to represent the patient 
perspective in the management of AF 
[24]. Thus, the number of studies that re-
ported QoL in AF has steadily increased 
in the last years. The instrument ‘typical-
ly used’ is the SF-36, but the SF-12 has al-
so been shown to provide robust results in 
the Birmingham Atrial Fibrillation Treat-
ment of the Aged study [25]. In IMPULS, 
two questionnaires were administered in 
a complimentary manner to assess QoL, 
namely the SF-12 and EQ-5D VAS as ge-
neric and the AF-QoL as disease-specific 
instrument [15, 16]. Generic instruments 
document general aspects of physical, 
mental or social functionality, which can 
similarly be compromised in diverse dis-
eases, and can be compared across these 
diseases using the instruments. Howev-
er, they are often less sensitive [19, 20] 
as health improvement and QoL instru-
ments are often not represented by a ge-
neric tool sufficiently [26]. Disease-spe-
cific questionnaires such as the AF-QoL 
focus on typical aspects of the disease, 
which may be experienced subjectively 
very differently by patients.
As it has been performed in a similar 
setting (office-based physicians in Ger-
152 | Herzschrittmachertherapie + Elektrophysiologie 2 · 2015
Original Contribution
Table 3 ADR leading to withdrawal of Multaq® (safety set)
System Organ Class Term Frequency % of patients
Cardiac disorders 80
Arrhythmia 2 0.36
Atrial fibrillation 60 10.38
Bradycardia 2 0.36
Cardiac failure 7 1.28
Left ventricular dysfunction 2 0.36
Palpitations 3 0.55
Tachyarrhythmia 2 0.36
General disorders and ad-
ministration site conditions
39
Condition aggravated 2 0.36
Drug ineffective 10 1.64
Drug intolerance 4 0.73
Fatigue 2 0.36
General physical health deterioration 2 0.36
Ill-defined disorder 4 0.73
Local swelling 2 0.36
Malaise 3 0.55
Oedema peripheral 2 0.36
Investigations 37
Alanine aminotransferase ↑ 12 2.19
Aspartate aminotransferase ↑ 2 0.36
Blood creatinine ↑ 3 0.55
Gamma-glutamyltransferase ↑ 2 0.36
Hepatic enzyme ↑ 4 0.73
International normalised ratio ↑ 2 0.36
Liver function test abnormal 3 0.55
Transaminases ↑ 4 0.73
Gastrointestinal disorders 27
Abdominal discomfort 5 0.91
Abdominal pain upper 2 0.36
Diarrhoea 7 1.28
Gastrointestinal disorder 2 0.36
Nausea 7 1.28




Dyspnoea exertional 2 0.36
Interstitial lung disease 2 0.36




Skin and subcutaneous tissue disorders 11
Hyperhidrosis 2 0.36
Rash 3 0.55
Table shows reactions that occurred in more than 1 patient. ↑, increased
many), the MOVE cross-sectional study 
is particularly useful to compare results 
[27]. On the 100-point VAS, the 3354 pa-
tients overall had a value of 68 ± 18 points 
(paroxysmal 70, persistent 68, perma-
nent 66 points) and thus a lower value 
compared with IMPULS (66 at baseline, 
74 at FU). As in MOVE, [27] QoL scores 
were slightly worse in women compared 
to men, for all types of AF. It was nota-
ble that during the FU of the study in IM-
PULS, QoL on all instruments was sub-
stantially improved with the greatest ef-
fect already at the first FU visit. The ob-
served improvement of 11 points on the 
VAS corresponds to a clinical improve-
ment of about one category in the Euro-
pean Heart Rhythm Association (EHRA) 
score (which is reported in four classes) 
and thus represents a significant effect 
[28]. This finding may be due to the clin-
ical effect of dronedarone, but could al-
so be an unspecific consequence of inten-
sive care of patients in the context of this 
study.
Limitations. A number of limitations 
need to be addressed when the current re-
sults are interpreted. Given IMPULS was 
an open-label non-randomised study, dif-
ferent biases can obscure any true caus-
al association [29]. As participating cen-
tres may have more scientific interest in 
particular in QoL investigations, results 
may not reflect outcomes in less well-or-
ganized institutions. Clinical decisions of 
the treating physicians may assign select-
ed patients to drug treatment guided by 
disease severity, presence of comorbidi-
ties and other factors. This can potential-
ly introduce allocation or channelling bi-
as and confound the association between 
treatment and outcomes. The sample size 
was relatively small, and therefore the 
study was not powered to detect previous-
ly unknown, rare side effects of dronedar-
one. FU periods longer than 1 year are de-
sirable to assess the long-term effects of 
the drug.
In conclusion, in this contemporary 
study on the use of dronedarone under 
clinical practice various dimensions of 
QoL of patients with AF were improved 
in the long term. No previously unknown 
safety issues were identified.
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